Evaluation and management of the man who has failed primary curative therapy for prostate cancer (Q33534842)

27 July 2017

1 reference

title

Evaluation and management of the man who has failed primary curative therapy for prostate cancer (English)

1 reference

27 July 2017

1 reference

Ornstein DK

1

1 reference

27 July 2017

Oh J

series ordinal

2

1 reference

27 July 2017

Herschman JD

series ordinal

3

1 reference

27 July 2017

Andriole GL

series ordinal

4

1 reference

27 July 2017

publication date

1 November 1998

1 reference

Urologic Clinics of North America

27 July 2017

published in

1 reference

27 July 2017

volume

25

1 reference

27 July 2017

issue

4

1 reference

27 July 2017

page(s)

591-601

1 reference

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Early complications of contemporary anatomical radical retropubic prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Correlations between radiography, ultrasonography, computed tomography and pathologic findings in prostatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Retroperitoneal and pelvic lymph node imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Biopsy after External Beam Radiation Therapy for Adenocarcinoma of the Prostate: Correlation with Original Histological Grade and Current Prostate Specific Antigen Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Magnetic resonance imaging for the diagnosis of prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Adjuvant radiotherapy following radical prostatectomy: results and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Effect of Adjuvant Radiation Therapy on Prostate Specific Antigen Following Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Value of transrectal ultrasound in identifying local disease after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The Effect of Radiation Therapy after Radical Prostatectomy in Patients with Elevated Prostate Specific Antigen Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate Specific Antigen and Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The Clinical Usefulness of Prostate Specific Antigen: Update 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The efficacy and complications of salvage cryotherapy of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Salvage surgery for radiation failure in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Magnetic resonance imaging for detection of prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Early detection of cancer relapse after prostatectomy using very sensitive prostate-specific antigen measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970050-1

7 January 2021

10.1016/S0094-0143(05)70050-1

Identifiers

DOI

1 reference

27 July 2017

1 reference